A case of unresectable huge hepatocellular carcinoma achieving complete response upon treatment with lenvatinib after split drug-eluting bead transarterial chemoembolization

DOI Web Site Web Site 15 References
  • Yoshii Hajime
    Department of Gastroenterology, Seirei Mikatahara General Hospital Department of Hepatology, Seirei Mikatahara General Hospital
  • Oshiro Keigo
    Department of Gastroenterology, Seirei Mikatahara General Hospital
  • Yamashita Ryu
    Department of Gastroenterology, Seirei Mikatahara General Hospital
  • Ohara Kazuto
    Department of Gastroenterology, Seirei Mikatahara General Hospital
  • Sato Yoshihisa
    Department of Gastroenterology, Seirei Mikatahara General Hospital
  • Kubota Nozomu
    Department of Gastroenterology, Seirei Mikatahara General Hospital
  • Yamada Satoshi
    Department of Gastroenterology, Seirei Mikatahara General Hospital
  • Tadauchi Akimitsu
    Department of Gastroenterology, Seirei Mikatahara General Hospital
  • Okai Ken
    Department of Gastroenterology, Seirei Mikatahara General Hospital Department of Hepatology, Seirei Mikatahara General Hospital

Bibliographic Information

Other Title
  • DEB-TACEとレンバチニブによる集学的治療により完全奏功が得られた巨大肝細胞癌の一例
  • DEB-TACE ト レンバチニブ ニ ヨル シュウガクテキ チリョウ ニ ヨリ カンゼン ソウコウ ガ エラレタ キョダイ カン サイボウ ガン ノ イチレイ

Search this article

Description

<p>An 81-year-old male with unresectable hepatocellular carcinoma (HCC) was treated with lenvatinib after split drug-eluting bead transarterial chemoembolization (DEB-TACE). He was referred to our department for the further examination of AST and ALT elevations. A 15-cm-diameter internal heterogeneous HCC occupied the left lobe of the liver. The tumor was unresectable and we initially performed split DEB-TACE to reduce the amount of tumor and to avoid adverse events including tumor lysis syndrome and postembolization syndrome. He was treated with DEB-TACE without any trouble except temporary elevations of both AST and ALT. After a series of DEB-TACE, CT images showed that residual HCC remained viable at the periphery of the tumor, and lenvatinib treatment was initiated. Three months after the initiation of lenvatinib treatment, a complete response was achieved, and serum AFP and PIVKA-2 levels declined to normal. Since then, CR has been maintained by continuing lenvatinib.</p>

Journal

  • Kanzo

    Kanzo 62 (8), 456-462, 2021-08-01

    The Japan Society of Hepatology

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top